Intestinal microenvironment-modulating nanomedicines for inflammatory bowel disease

Inflammatory bowel diseases present a highly restrictive intestinal microenvironment for drug delivery, in which epithelial injury, chronic inflammation, and microbial dysbiosis collectively impair transport, retention, and therapeutic efficacy. Excessive reactive oxygen species (ROS), mucus barrier disruption, altered luminal acidity, hydrogen sulfide accumulation, and abnormal enzymatic activity destabilize therapeutic cargos and limit access to inflamed tissues. These pathological features have motivated the development of nanocarriers designed either to directly modulate biochemical abnormalities, such as ROS scavenging and H₂S removal, or to respond to disease-associated biochemical cues including ROS, luminal pH, enzymatic activity, and mucus abnormalities. In parallel, modulation of the immunological microenvironment has been pursued through nanomedicine platforms engineered to regulate inflammatory signaling, enhance mucosal targeting, protect therapeutic payloads from premature degradation, and prolong local residence. Complementary microbiome-oriented delivery strategies, including engineered probiotics, nanoparticles that release postbiotic factors, and carriers coated with microbial membranes, leverage host microbe interactions to achieve localized and sustained therapeutic effects. Despite substantial progress, effective delivery remains constrained by patient specific variability, spatial heterogeneity of inflammatory conditions, and limited durability of mucosal retention. Integrating biochemical responsiveness, immune modulation, and microbiome informed targeting represents a promising direction for advancing precision nanomedicine in inflammatory bowel diseases.